Compare Equinix Inc (EQIX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Incyte Corporation — how do they compare? Equinix Inc trades at $1,027.6 (market cap $99.77B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Equinix Inc is far larger — about 4.4× Incyte Corporation's market cap, and Equinix Inc pays a 2.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Incyte Corporation for 33 Days on average.
| EQIX | INCY | |
|---|---|---|
Market Cap | $99.77B | $22.85B |
Volume | 480,425 | 1,927,029 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $129.93 |
52-Week Low | $726.09 | $83.80 |
Typical Hold Time | 110 Days | 33 Days |
Enterprise Value | $120.90B | $18.35B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,019.70, down 1.17% on the day, with a bearish technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong revenue growth, reaching $9.22B in 2025, and a net income margin of 15.63%, but faces high valuation ratios like a P/E of 65.07. Recent news highlights AI-driven data center demand and a $5B-$7B annual buildout plan, supporting long-term growth prospects amid significant capital expenditures.
The outlook for EQIX is cautiously optimistic, with Wall Street analysts largely bullish (75% buy ratings) and a consensus price target of $1,250 offering ~22% upside. Key risks include elevated debt levels, with debt-to-asset ratio rising to 47.13% in 2025, and sustained negative cash flow from aggressive expansion investments. Investors should weigh strong AI-driven demand against execution risks and high valuation multiples.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
